Alleviating Effects Against Dry Eye by Oral Intake of Cordyceps Cicadae Mycelia
1 other identifier
interventional
97
0 countries
N/A
Brief Summary
Cordyceps cicadae mycelia was tested for amelioration of dry eye symptoms through dietary supplementation. Its efficacy in relief of human dry eye status was assessed by randomized, double-blinded tests, including multiple assessments. The results were compared between the placebo group and the experimental group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2016
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 7, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2017
CompletedFirst Submitted
Initial submission to the registry
August 15, 2019
CompletedFirst Posted
Study publicly available on registry
August 21, 2019
CompletedAugust 21, 2019
August 1, 2019
2 months
August 15, 2019
August 19, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
tear film breakup time
Tear film breakup time was used for tear quality assessments.
day 1 to day 90.
Cornea surface scores based on Efron grading system
Cornea surface scores based on Efron grading system was used for assessment of cornea surface damages.
day 1 to day 90.
Intra-ocular pressure
Intra-ocular pressure was taken to assess eye pressure.
day 1 to day 90.
Study Arms (2)
Experimental group
EXPERIMENTALsupplement was given for 3 months.
Placebo group
PLACEBO COMPARATORPlacebo was given for 3 months.
Interventions
Cordyceps Cicadae Mycelia supplement for 3 months
Eligibility Criteria
You may qualify if:
- Adults aged from 20 to 60 with dry eye symptoms confirmed by ophthalmologists, and without chronic diseases.
You may not qualify if:
- Those vulnerable to damages or loss of self-conscious, or behavior capacity, or with major illness or with critical diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- David Pei-Cheng Linlead
- Grape King Bio Ltd.collaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David Pei-Cheng Lin, PhD
Chung Shan Medical University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 15, 2019
First Posted
August 21, 2019
Study Start
December 1, 2016
Primary Completion
February 7, 2017
Study Completion
November 30, 2017
Last Updated
August 21, 2019
Record last verified: 2019-08
Data Sharing
- IPD Sharing
- Will not share